Just shy of its 1-year anniversary, radiopharmaceuticals platform play RayzeBio bags another megaround
Perhaps they should have called it RaiseBio.
Not even a full year post-launch, RayzeBio’s radiopharmaceuticals platform has hooked yet another $100 million-plus raise, and it appears the company’s next big catch will be a Nasdaq ticker.
CEO Ken Song unveiled the Series C round Tuesday morning, bringing the fledgling biotech’s total raise to $258 million. While he was hesitant to call it a crossover round, he said it very well could be RayzeBio’s last private round of financing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.